Published in Cancer Weekly, December 24th, 2002
The agreement, the second GSK-Coley license agreement, provides GSK with a worldwide nonexclusive license to Coley's proprietary CpG immunostimulatory oligos for use as adjuvants in cancer vaccines. In exchange, Coley has received $4 million in license issue fees and upon the achievement of certain milestones, will receive future payments, as well as license maintenance fees and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.